Guardant Health receives European approval for breast cancer test
Guardant Health Inc. (GH) received CE-marking for its Guardant360 CDx test in Europe, aiding breast cancer treatment decisions. The test identifies ESR1 mutations for AstraZeneca's ETCAMAH. This is GH's 31st companion diagnostic approval, previously cleared in the U.S. and Japan.
How this was made
The 30-second read
Why it matters
The CE-mark approval under Europe’s IVDR framework allows the test to identify estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer patients who may benefit from camizestrant.
Market read
A new Europe regulatory milestone for a companion diagnostic tied to a specific therapy and indication can shift expectations for EU adoption and future diagnostic volumes.
What to watch
Traders may need to watch for EU reimbursement timelines, competitive landscape for ESR1 testing, and whether camizestrant uptake in breast cancer accelerates in parallel.
Background
Guardant360 CDx is a liquid biopsy test detecting ESR1 mutations and is used as a companion diagnostic for camizestrant (ETCAMAH) in advanced breast cancer.
Ticker impact
Guardant Health says its Guardant360 CDx received CE-marking in Europe as a companion diagnostic for camizestrant in breast cancer.
Likely upward bias as the market prices in broader EU reimbursement and uptake for the companion diagnostic franchise.
The article is a direct regulatory approval for the company’s product and links it to a specific therapy and breast cancer indication, which can improve addressable demand versus prior US/Japan-only approvals.
Market effects
Reinforces momentum for liquid biopsy companion diagnostics and may support sentiment toward precision oncology diagnostics in Europe.
Improves Guardant’s EU market access narrative for breast cancer companion diagnostic use.
Adds to the global regulatory footprint (US, Japan, now Europe) for the same diagnostic-therapy pairing.
Counterpoint
CE-marking does not guarantee broad reimbursement or rapid clinical adoption; near-term revenue impact may be limited until payer coverage and ordering ramp.
Key entities
- companyGuardant Health Inc.
Receives CE-marking for Guardant360 CDx as a companion diagnostic for camizestrant in breast cancer.
- productGuardant360 CDx
Liquid biopsy test detecting ESR1 mutations via blood draw for treatment selection.
- therapyETCAMAH (camizestrant)
Oral selective estrogen receptor degrader referenced as the therapy companion diagnostic.
- companyAstraZeneca
Company whose camizestrant is the therapy linked to the companion diagnostic approval.
